Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQW612)

Drug Name

Ad5f35-LMPd1-2-transduced autologous dendritic cells Drug Info

Synonyms

AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI

Indication

Disease Entry	ICD 11	Status	REF
Nasopharyngeal carcinoma	2B6B	Investigative	[1]

Cross-matching ID

TTD Drug ID: DMQW612

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Epstein-Barr virus Latent membrane protein 2 (EBV LMP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LMP-1/LMP-2 CTLs	DMZU2G1	Lymphoma	2A80-2A86	Phase 1	[2]
------------------------------------------------------------------------------------

Drug(s) Targeting Epstein-Barr virus Latent membrane protein 1 (EBV LMP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LMP1-CAR-T cells	DMYGNDI	Nasopharyngeal carcinoma	2B6B	Phase 1/2	[3]
LMP-1/LMP-2 CTLs	DMZU2G1	Lymphoma	2A80-2A86	Phase 1	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epstein-Barr virus Latent membrane protein 1 (EBV LMP1)	TT0BI4Q	LMP1_EBVG	Not Available	[1]
Epstein-Barr virus Latent membrane protein 2 (EBV LMP2)	TTBK351	LMP2_EBVB9	Not Available	[1]

------------------------------------------------------------------------------------

References

1	CA patent application no. 876139, Nanotherapeutics for drug targeting.
2	In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42.
3	ClinicalTrials.gov (NCT02980315) A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application